Vertex shares attractive, says ThinkEquity After Vertex presented key efficacy and safety data for VX809 combination therapy, ThinkEquity believes that the data suggests that the therapy is providing a clinical benefit. The firm thinks that this benefit could be replicated in a Phase III study and it suggests owning the stock. ThinkEquity maintains a Buy rating on the shares.
Gilead paying premium to buy Vertex not warranted right now, says Maxim After Bernstein suggested in a note to investors earlier that Gilead (GILD) should buy Vertex (VRTX), Maxim responded in its own note that it does not believe paying a premium to buy Vertex makes sense before the company has data showing efficacy for Kalydeco in heterozygotes. Maxim keeps a Hold rating and $121 price target on Vertex shares.